HMP Global December 18, 2024
Katie Hayes, MJ

The 118th Congress is wrapping up with a whimper rather than a bang when it comes to health care legislation, particularly compared to its predecessor’s transformative impact on pharmaceutical policy. As we reflect on these past 4 years, the contrast between legislative accomplishments couldn’t be starker, especially for pharmaceutical manufacturers navigating an increasingly complex regulatory landscape.

The 117th’s Landmark Achievement

The 117th Congress fundamentally altered the pharmaceutical landscape through the Inflation Reduction Act (IRA), marking a historic shift in federal authority over drug pricing. After decades of pharmaceutical industry opposition and failed legislative attempts, Democrats successfully leveraged their slim majority to implement what many consider the most significant drug pricing reform since Medicare Part D’s creation.

The IRA’s drug pricing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Congress / White House, Govt Agencies
Congress proposes temporary 2.5% physician pay bump in new healthcare package
Congress' AI report leaves some tech-watchers on edge
Health care package winners and losers
Temporary Federal Funding Bill Addresses SUPPORT Act Reauthorization, Ghost Networks and Telehealth Flexibilities
Stopgap funding bill includes sweeping PBM reform, preserves telehealth flexibilities

Share This Article